2026-2034年全球临床肿瘤学次世代定序市场规模、份额、趋势和成长分析报告

预计到 2034 年，临床肿瘤学中次世代定序的市场规模将从 2025 年的 6 亿美元成长到 22.9 亿美元，2026 年至 2034 年的复合年增长率为 15.97%。

由于对精准癌症诊断的需求不断增长，全球临床肿瘤学领域次世代定序市场正经历快速成长。次世代定序（NGS）技术能够对肿瘤进行全面的基因组分析，从而支持标靶治疗的发展。癌症发生率的上升以及人们对个人化治疗方案认识的不断提高，正在推动全球市场的扩张。

关键成长要素包括定序技术的进步和定序成本的降低。医疗机构越来越多地采用新一代定序（NGS）技术进行癌症早期检测和病情进展监测。临床研究的拓展和政府资助的增加进一步推动了市场成长。此外，製药公司也正在利用基因组数据进行药物研发和伴随诊断。

展望未来，人工智慧驱动的生物资讯工具与液态生物检体应用的融合有望推动市场发展。新兴国家肿瘤医疗基础设施的改善将创造新的成长机会。各公司正致力于提高检测准确性并缩短处理时间。随着精准肿瘤学逐渐成为标准治疗方案，全球临床肿瘤学次世代定序市场预计将持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球临床肿瘤学次世代定序市场：依技术划分

• 市场分析、洞察与预测
• 全基因测序
• 全EXOME定序
• 标靶定序和定序

第五章：全球临床肿瘤学次世代定序市场：依工作流程划分

• 市场分析、洞察与预测
• NGS定序预处理
• 次世代定序
• NGS数据分析

第六章：全球临床肿瘤学次世代定序市场：按应用领域划分

• 市场分析、洞察与预测
• 筛检（散发性癌症、遗传性癌症）
• 伴随诊断
• 其他诊断

第七章 全球临床肿瘤学次世代定序市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 诊所
• 研究所

第八章：全球临床肿瘤学次世代定序市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Illumina Inc
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies
  • Myriad Genetics
  • Beijing Genomics Institute（BGI）
  • PerkinElmer
  • Foundation Medicine
  • Pacific Biosciences（PacBio）
  • Oxford Nanopore Technologies Ltd
  • Paradigm Diagnostics
  • Caris Life Sciences
  • Partek Inc
  • Eurofins Scientific SE
  • Qiagen NV

The Clinical Oncology Next Generation Sequencing Market size is expected to reach USD 2.29 Billion in 2034 from USD 0.60 Billion (2025) growing at a CAGR of 15.97% during 2026-2034.

The Global Clinical Oncology Next Generation Sequencing Market is witnessing rapid growth due to increasing demand for precision cancer diagnostics. Next generation sequencing (NGS) enables comprehensive genomic profiling of tumors, supporting targeted therapy decisions. Rising cancer prevalence and growing awareness of personalized treatment approaches are driving market expansion worldwide.

Key growth drivers include advancements in sequencing technologies and decreasing sequencing costs. Healthcare providers are increasingly adopting NGS for early detection and monitoring of cancer progression. Expanding clinical research and supportive government funding are further strengthening market growth. Additionally, pharmaceutical companies are utilizing genomic data for drug development and companion diagnostics.

Looking ahead, the market is expected to benefit from integration of AI-driven bioinformatics tools and liquid biopsy applications. Emerging economies improving oncology care infrastructure will present new growth opportunities. Companies are focusing on enhancing accuracy and reducing turnaround times. As precision oncology becomes standard practice, the Global Clinical Oncology Next Generation Sequencing Market is poised for sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

By Workflow

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

By Application

• Screening (Sporadic Cancer, Inherited Cancer)
• Companion Diagnostics
• Other Diagnostics

By End-use

• Hospitals
• Clinics
• Laboratories

COMPANIES PROFILED

• Illumina Inc, Thermo Fisher Scientific, F HoffmannLa Roche Ltd, Agilent Technologies, Myriad Genetics, Beijing Genomics Institute BGI, PerkinElmer, Foundation Medicine, Pacific Biosciences PacBio, Oxford Nanopore Technologies Ltd, Paradigm Diagnostics, Caris Life Sciences, Partek Inc, Eurofins Scientific SE, Qiagen NV
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Whole Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Whole Exome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Targeted Sequencing & Resequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. NGS Pre-Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. NGS Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. NGS Data Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Screening (Sporadic Cancer, Inherited Cancer) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Technology
  • 8.2.2 By Workflow
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Technology
  • 8.3.2 By Workflow
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Technology
  • 8.4.2 By Workflow
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Technology
  • 8.5.2 By Workflow
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Technology
  • 8.6.2 By Workflow
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Illumina Inc
  • 10.2.2 Thermo Fisher Scientific
  • 10.2.3 F. Hoffmann-La Roche Ltd
  • 10.2.4 Agilent Technologies
  • 10.2.5 Myriad Genetics
  • 10.2.6 Beijing Genomics Institute (BGI)
  • 10.2.7 PerkinElmer
  • 10.2.8 Foundation Medicine
  • 10.2.9 Pacific Biosciences (PacBio)
  • 10.2.10 Oxford Nanopore Technologies Ltd
  • 10.2.11 Paradigm Diagnostics
  • 10.2.12 Caris Life Sciences
  • 10.2.13 Partek Inc
  • 10.2.14 Eurofins Scientific S.E
  • 10.2.15 Qiagen N.V